Yahoo
NasdaqCM - Delayed Quote USD

Alpha Cognition Inc. (ACOG)

9.52 +0.31 (+3.37%)
At close: September 4 at 4:00:00 PM EDT
9.52 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade ACOG on Coinbase
Chart Range Bar
Loading chart for ACOG
  • Previous Close 9.21
  • Open 9.22
  • Bid 9.38 x 100
  • Ask 17.00 x 100
  • Day's Range 9.10 - 9.52
  • 52 Week Range 4.50 - 10.14
  • Volume 45,559
  • Avg. Volume 105,607
  • Market Cap (intraday) 207.325M
  • Beta (5Y Monthly) 2.24
  • PE Ratio (TTM) --
  • EPS (TTM) -0.99
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.00

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

www.alphacognition.com

71

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ACOG
46.46%
S&P 500 (^GSPC)
12.75%

1-Year Return

ACOG
14.01%
S&P 500 (^GSPC)
18.71%

3-Year Return

ACOG
36.00%
S&P 500 (^GSPC)
70.93%

5-Year Return

ACOG
36.00%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 3.53M
Earnings -6.48M
Profit Margin -183.32%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-10M
-5M
0
-600.0%
-400.0%
-200.0%

Analyst Insights

View More

Analyst Price Targets

12.00
18.00 Average
9.52 Current
21.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/20/2026
Analyst B. Riley Securities
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 21

Statistics

View More

Valuation Measures

Annual
As of 9/2/2026
  • Market Cap

    202.86M

  • Enterprise Value

    155.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.58

  • Price/Book (mrq)

    3.83

  • Enterprise Value/Revenue

    10.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -137.70%

  • Return on Assets (ttm)

    -30.40%

  • Return on Equity (ttm)

    -49.53%

  • Revenue (ttm)

    15.26M

  • Net Income Avi to Common (ttm)

    -21.01M

  • Diluted EPS (ttm)

    -0.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    41.38M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -28.53M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

9.52 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: